A Study of LY3437943 in Participants With Type 2 Diabetes
Completed · Phase 2 · NCT04867785
Conditions: Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $21,822
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 281
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3437943 (drug), Dulaglutide (drug), Placebo (drug)
- Dates
- Started 2021-05-13; completion 2022-10-27
- Results posted
- Yes
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
From ClinicalTrials.gov, last updated 2023-07-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $21,822 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mark T. Leibowitz, M.D. Internal Medicine · Long Beach, CA
- Juan P. Loy, M.D. Internal Medicine · Margate, FL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $20,760
- South Florida Wellness and Clinical Resear $1,062
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.